PD-L1 expression is associated with tumor FOXP3+regulatory T-cell infiltration of breast cancer and poor prognosis of patient

Journal of Cancer

Volumn 7, Issue 7, 2016, Pages 784-793

  Li, Zhenhua ^a   Dong, Pengzhi ^b   Ren, Meijing ^a   Song, Yawen ^a   Qian, Xiaolong ^a   Yang, Yiling ^a   Li, Shuai ^a   Zhang, Xinmin ^c   Liu, Fangfang ^a  

^a TIANJIN MEDICAL UNIVERSITY   (China)

^b TIANJIN UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

^c UMDNJ Robert Wood Johnson Medical School at Camden   (United States)

Author keywords

Breast cancer; FOXP3+Tregs; Intrinsic subtype; PD L1; Prognosis

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGRAMMED DEATH 1 LIGAND 1; PROSTAGLANDIN RECEPTOR; TRANSCRIPTION FACTOR FOXP3;

ADULT; ARTICLE; BREAST CANCER; CANCER PROGNOSIS; CELL INFILTRATION; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; TUMOR ESCAPE;

EID: 84982802695     PISSN: None     EISSN: 18379664     Source Type: Journal    
DOI: 10.7150/jca.14549     Document Type: Article

References (51)

1. Butte MJ, Pena-Cruz V, Kim MJ, Freeman GJ, Sharpe AH. Interaction of human PD-L1 and B7-1. Molecular immunology. 2008; 45: 3567-72. doi:10.1016/j.molimm.2008.05.014.
2. Droeser RA, Hirt C, Viehl CT, Frey DM, Nebiker C, Huber X, et al. Clinical impact of programmed cell death ligand 1 expression in colorectal cancer. European journal of cancer. 2013; 49: 2233-42. doi:10.1016/j.ejca.2013.02.015.
3. Chen YB, Mu CY, Huang JA. Clinical significance of programmed death-1 ligand-1 expression in patients with non-small cell lung cancer: a 5-year-follow-up study. Tumori. 2012; 98: 751-5. doi:10.1700/1217.13499.
4. Hamanishi J, Mandai M, Iwasaki M, Okazaki T, Tanaka Y, Yamaguchi K, et al. Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer. Proceedings of the National Academy of Sciences of the United States of America. 2007; 104: 3360-5. doi:10.1073/pnas.0611533104.
5. Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. The New England journal of medicine. 2012; 366: 2455-65. doi:10.1056/NEJMoa1200694.
6. Herbst RS, Soria JC, Kowanetz M, Fine GD, Hamid O, Gordon MS, et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature. 2014; 515: 563-7. doi:10.1038/nature14011.
7. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. The New England journal of medicine. 2010; 363: 711-23. doi:10.1056/NEJMoa1003466.
8. Powles T, Eder JP, Fine GD, Braiteh FS, Loriot Y, Cruz C, et al. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature. 2014; 515: 558-62. doi:10.1038/nature13904.
9. Ghebeh H, Mohammed S, Al-Omair A, Qattan A, Lehe C, Al-Qudaihi G, et al. The B7-H1 (PD-L1) T lymphocyte-inhibitory molecule is expressed in breast cancer patients with infiltrating ductal carcinoma: correlation with important high-risk prognostic factors. Neoplasia. 2006; 8: 190-8. doi:10.1593/neo.05733.
10. Ghebeh H, Tulbah A, Mohammed S, Elkum N, Bin Amer SM, Al-Tweigeri T, et al. Expression of B7-H1 in breast cancer patients is strongly associated with high proliferative Ki-67-expressing tumor cells. International journal of cancer Journal international du cancer. 2007; 121: 751-8. doi:10.1002/ijc.22703.
11. Muenst S, Schaerli AR, Gao F, Daster S, Trella E, Droeser RA, et al. Expression of programmed death ligand 1 (PD-L1) is associated with poor prognosis in human breast cancer. Breast cancer research and treatment. 2014; 146: 15-24. doi:10.1007/s10549-014-2988-5.
12. Schalper KA, Velcheti V, Carvajal D, Wimberly H, Brown J, Pusztai L, et al. In situ tumor PD-L1 mRNA expression is associated with increased TILs and better outcome in breast carcinomas. Clinical cancer research: an official journal of the American Association for Cancer Research. 2014; 20: 2773-82. doi:10.1158/1078-0432.CCR-13-2702.
13. Yagi H, Nomura T, Nakamura K, Yamazaki S, Kitawaki T, Hori S, et al. Crucial role of FOXP3 in the development and function of human CD25+CD4+ regulatory T cells. International immunology. 2004; 16: 1643-56. doi:10.1093/intimm/dxh165.
14. Campbell DJ, Ziegler SF. FOXP3 modifies the phenotypic and functional properties of regulatory T cells. Nature reviews Immunology. 2007; 7: 305-10. doi:10.1038/nri2061.
15. Fontenot JD, Gavin MA, Rudensky AY. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nature immunology. 2003; 4: 330-6. doi:10.1038/ni904.
16. Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science. 2003; 299: 1057-61. doi:10.1126/science.1079490.
17. Khattri R, Cox T, Yasayko SA, Ramsdell F. An essential role for Scurfin in CD4+CD25+ T regulatory cells. Nature immunology. 2003; 4: 337-42. doi:10.1038/ni909.
18. Schreiber TH. The use of FoxP3 as a biomarker and prognostic factor for malignant human tumors. Cancer epidemiology, biomarkers & prevention: a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 2007; 16: 1931-4. doi:10.1158/1055-9965.EPI-07-0396.
19. Liu F, Lang R, Zhao J, Zhang X, Pringle GA, Fan Y, et al. CD8(+) cytotoxic T cell and FOXP3(+) regulatory T cell infiltration in relation to breast cancer survival and molecular subtypes. Breast cancer research and treatment. 2011; 130: 645-55. doi:10.1007/s10549-011-1647-3.
20. Liu F, Li Y, Ren M, Zhang X, Guo X, Lang R, et al. Peritumoral FOXP3(+) regulatory T cell is sensitive to chemotherapy while intratumoral FOXP3(+) regulatory T cell is prognostic predictor of breast cancer patients. Breast cancer research and treatment. 2012; 135: 459-67. doi:10.1007/s10549-012-2132-3.
21. Francisco LM, Salinas VH, Brown KE, Vanguri VK, Freeman GJ, Kuchroo VK, et al. PD-L1 regulates the development, maintenance, and function of induced regulatory T cells. J Exp Med. 2009; 206: 3015-29. doi:10.1084/jem.20090847.
22. Krupnick AS, Gelman AE, Barchet W, Richardson S, Kreisel FH, Turka LA, et al. Murine vascular endothelium activates and induces the generation of allogeneic CD4+25+Foxp3+ regulatory T cells. Journal of immunology. 2005; 175: 6265-70.
23. Park JJ, Omiya R, Matsumura Y, Sakoda Y, Kuramasu A, Augustine MM, et al. B7-H1/CD80 interaction is required for the induction and maintenance of peripheral T-cell tolerance. Blood. 2010; 116: 1291-8. doi:10.1182/blood-2010-01-265975.
24. Ni XY, Sui HX, Liu Y, Ke SZ, Wang YN, Gao FG. TGF-beta of lung cancer microenvironment upregulates B7H1 and GITRL expression in dendritic cells and is associated with regulatory T cell generation. Oncology reports. 2012; 28: 615-21. doi:10.3892/or.2012.1822.
25. Wang L, Pino-Lagos K, de Vries VC, Guleria I, Sayegh MH, Noelle RJ. Programmed death 1 ligand signaling regulates the generation of adaptive Foxp3+CD4+ regulatory T cells. Proceedings of the National Academy of Sciences of the United States of America. 2008; 105: 9331-6. doi:10.1073/pnas.0710441105.
26. Zhao LW, Li C, Zhang RL, Xue HG, Zhang FX, Zhang F, et al. B7-H1 and B7-H4 expression in colorectal carcinoma: correlation with tumor FOXP3(+) regulatory T-cell infiltration. Acta histochemica. 2014; 116: 1163-8. doi:10.1016/j.acthis.2014.06.003.
27. Hou J, Yu Z, Xiang R, Li C, Wang L, Chen S, et al. Correlation between infiltration of FOXP3+ regulatory T cells and expression of B7-H1 in the tumor tissues of gastric cancer. Experimental and molecular pathology. 2014; 96: 284-91. doi:10.1016/j.yexmp.2014.03.005.
28. Geng Y, Wang H, Lu C, Li Q, Xu B, Jiang J, et al. Expression of costimulatory molecules B7-H1, B7-H4 and Foxp3(+) Tregs in gastric cancer and its clinical significance. International journal of clinical oncology. 2015; 20: 273-81. doi:10.1007/s10147-014-0701-7.
29. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM, et al. REporting recommendations for tumor MARKer prognostic studies (REMARK). Breast cancer research and treatment. 2006; 100: 229-35. doi:10.1007/s10549-006-9242-8.
30. Dong H, Strome SE, Salomao DR, Tamura H, Hirano F, Flies DB, et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nature medicine. 2002; 8: 793-800. doi:10.1038/nm730.
31. Latchman YE, Liang SC, Wu Y, Chernova T, Sobel RA, Klemm M, et al. PD-L1-deficient mice show that PD-L1 on T cells, antigen-presenting cells, and host tissues negatively regulates T cells. Proceedings of the National Academy of Sciences of the United States of America. 2004; 101: 10691-6. doi:10.1073/pnas.0307252101.
32. Azuma T, Yao S, Zhu G, Flies AS, Flies SJ, Chen L. B7-H1 is a ubiquitous antiapoptotic receptor on cancer cells. Blood. 2008; 111: 3635-43. doi:10.1182/blood-2007-11-123141.
33. Soliman H, Khalil F, Antonia S. PD-L1 expression is increased in a subset of basal type breast cancer cells. PloS one. 2014; 9: e88557. doi:10.1371/journal.pone.0088557.
34. Mittendorf EA, Philips AV, Meric-Bernstam F, Qiao N, Wu Y, Harrington S, et al. PD-L1 expression in triple-negative breast cancer. Cancer immunology research. 2014; 2: 361-70. doi:10.1158/2326-6066.CIR-13-0127.
35. Zang X, Allison JP. The B7 family and cancer therapy: costimulation and coinhibition. Clinical cancer research: an official journal of the American Association for Cancer Research. 2007; 13: 5271-9. doi:10.1158/1078-0432.CCR-07-1030.
36. Hino R, Kabashima K, Kato Y, Yagi H, Nakamura M, Honjo T, et al. Tumor cell expression of programmed cell death-1 ligand 1 is a prognostic factor for malignant melanoma. Cancer. 2010; 116: 1757-66. doi:10.1002/cncr.24899.
37. Hasan A, Ghebeh H, Lehe C, Ahmad R, Dermime S. Therapeutic targeting of B7-H1 in breast cancer. Expert opinion on therapeutic targets. 2011; 15: 1211-25. doi:10.1517/14728222.2011.613826.
38. Mu CY, Huang JA, Chen Y, Chen C, Zhang XG. High expression of PD-L1 in lung cancer may contribute to poor prognosis and tumor cells immune escape through suppressing tumor infiltrating dendritic cells maturation. Medical oncology. 2011; 28: 682-8. doi:10.1007/s12032-010-9515-2.
39. Song M, Chen D, Lu B, Wang C, Zhang J, Huang L, et al. PTEN loss increases PD-L1 protein expression and affects the correlation between PD-L1 expression and clinical parameters in colorectal cancer. PloS one. 2013; 8: e65821. doi:10.1371/journal.pone.0065821.
40. Ali HR, Glont SE, Blows FM, Provenzano E, Dawson SJ, Liu B, et al. PD-L1 protein expression in breast cancer is rare, enriched in basal-like tumours and associated with infiltrating lymphocytes. Annals of oncology: official journal of the European Society for Medical Oncology / ESMO. 2015. doi:10.1093/annonc/mdv192.
41. Sabatier R, Finetti P, Mamessier E, Adelaide J, Chaffanet M, Ali HR, et al. Prognostic and predictive value of PDL1 expression in breast cancer. Oncotarget. 2015; 6: 5449-64.
42. Burton OT, Zaccone P, Phillips JM, De La Pena H, Fehervari Z, Azuma M, et al. Roles for TGF-beta and programmed cell death 1 ligand 1 in regulatory T cell expansion and diabetes suppression by zymosan in nonobese diabetic mice. Journal of immunology. 2010; 185: 2754-62. doi:10.4049/jimmunol.1001365.
43. Zhao Y, Huang Z, Qi M, Lazzarini P, Mazzone T. Immune regulation of T lymphocyte by a newly characterized human umbilical cord blood stem cell. Immunology letters. 2007; 108: 78-87. doi:10.1016/j.imlet.2006.10.007.
44. Jin HT, Ahmed R, Okazaki T. Role of PD-1 in regulating T-cell immunity. Current topics in microbiology and immunology. 2011; 350: 17-37. doi:10.1007/82_2010_116.
45. Ghebeh H, Barhoush E, Tulbah A, Elkum N, Al-Tweigeri T, Dermime S. FOXP3+ Tregs and B7-H1+/PD-1+ T lymphocytes co-infiltrate the tumor tissues of high-risk breast cancer patients: Implication for immunotherapy. BMC cancer. 2008; 8: 57. doi:10.1186/1471-2407-8-57.
46. Ascierto PA, Simeone E, Sznol M, Fu YX, Melero I. Clinical experiences with anti-CD137 and anti-PD1 therapeutic antibodies. Seminars in oncology. 2010; 37: 508-16. doi:10.1053/j.seminoncol.2010.09.008.
47. Brahmer JR, Drake CG, Wollner I, Powderly JD, Picus J, Sharfman WH, et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2010; 28: 3167-75. doi:10.1200/JCO.2009.26.7609.
48. Emens LB, Cassier P, DeLord J-P, Eder JP, Shen X, Xiao Y, et al. Inhibition of PD-L1 by MPDL3280A leads to clinical activity in patients with metastatic triple-negative breast cancer. San Antonio Breast Cancer Symposium. 2014; 2014 PD1-6.
49. Nanda RC, Dees EC, Berger R, Gupta S, Geva R, Pusztai L, et al. A phase Ib study of pembrolizumab (MK-3475) in patients with advanced triple-negative breast cancer. San Antonio Breast Cancer Symposium. 2014;: S1-09.
50. Gibson J. Anti-PD-L1 for metastatic triple-negative breast cancer. The Lancet Oncology. 2015. doi:10.1016/S1470-2045(15)70208-1.
51. Webster WS, Thompson RH, Harris KJ, Frigola X, Kuntz S, Inman BA, et al. Targeting molecular and cellular inhibitory mechanisms for improvement of antitumor memory responses reactivated by tumor cell vaccine. Journal of immunology. 2007; 179: 2860-9.